

Silvia Romano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7420011/publications.pdf>

Version: 2024-02-01

107
papers

3,700
citations

159358

30
h-index

138251

58
g-index

118
all docs

118
docs citations

118
times ranked

5600
citing authors

#	ARTICLE	IF	CITATIONS
1	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. <i>Neurology</i> , 2012, 78, 690-695.	1.5	303
2	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
3	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	4.9	248
4	CD161 ^{high} CD8 ⁺ T cells bear pathogenetic potential in multiple sclerosis. <i>Brain</i> , 2011, 134, 542-554.	3.7	211
5	Riluzole in cerebellar ataxia. <i>Neurology</i> , 2010, 74, 839-845.	1.5	171
6	Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. <i>Brain</i> , 2008, 131, 2321-2331.	3.7	169
7	Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 985-991.	4.9	163
8	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 82, 41-48.	1.5	128
9	Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. <i>PLOS Currents</i> , 2010, 2, RRN1184.	1.4	124
10	Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 442-446.	1.4	107
11	Can MR Imaging Diagnose Adult-Onset Alexander Disease?. <i>American Journal of Neuroradiology</i> , 2008, 29, 1190-1196.	1.2	99
12	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
13	Normal and mutant <i>HTT</i> interact to affect clinical severity and progression in Huntington disease. <i>Neurology</i> , 2009, 73, 1280-1285.	1.5	84
14	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1409-1412.	0.9	82
15	Suicidal ideation in a European Huntington's disease population. <i>Journal of Affective Disorders</i> , 2013, 151, 248-258.	2.0	74
16	A Candidate-Interactome Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63300.	1.1	66
17	Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. <i>Journal of the Neurological Sciences</i> , 2010, 291, 30-36.	0.3	63
18	Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2018, 15, 68-74.	2.1	55

#	ARTICLE	IF	CITATIONS
19	Cognitive decline in Huntington's disease expansion gene carriers. <i>Cortex</i> , 2017, 95, 51-62.	1.1	50
20	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. <i>PLoS ONE</i> , 2013, 8, e68951.	1.1	49
21	Procerus sign in progressive supranuclear palsy. <i>Neurology</i> , 2001, 57, 1928-1928.	1.5	46
22	Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. <i>Current Opinion in Immunology</i> , 2018, 55, 89-96.	2.4	45
23	Epstein-Barr virus genetic variants are associated with multiple sclerosis. <i>Neurology</i> , 2015, 84, 1362-1368.	1.5	44
24	Structural cerebellar correlates of cognitive functions in spinocerebellar ataxia type 2. <i>Journal of Neurology</i> , 2018, 265, 597-606.	1.8	44
25	Corticosteroids treatment. <i>Journal of the Neurological Sciences</i> , 2004, 223, 47-51.	0.3	43
26	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. <i>Frontiers in Immunology</i> , 2019, 10, 1916.	2.2	39
27	Fractal Analysis Reveals Reduced Complexity of Retinal Vessels in CADASIL. <i>PLoS ONE</i> , 2011, 6, e19150.	1.1	39
28	Clinical manifestations of intermediate allele carriers in Huntington disease. <i>Neurology</i> , 2016, 87, 571-578.	1.5	37
29	Neural substrates of motor and cognitive dysfunctions in SCA2 patients: A network based statistics analysis. <i>NeuroImage: Clinical</i> , 2017, 14, 719-725.	1.4	36
30	A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. <i>Scientific Reports</i> , 2017, 7, 45780.	1.6	31
31	Microstructural MRI Basis of the Cognitive Functions in Patients with Spinocerebellar Ataxia Type 2. <i>Neuroscience</i> , 2017, 366, 44-53.	1.1	31
32	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316.	0.9	30
33	Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0230219.	1.1	30
34	<i>GFAP </i>mutations and polymorphisms in 13 unrelated Italian patients affected by Alexander disease. <i>Clinical Genetics</i> , 2007, 72, 427-433.	1.0	29
35	IFN- γ and multiple sclerosis: From etiology to therapy and back. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 221-228.	3.2	28
36	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. <i>Annals of Neurology</i> , 2019, 85, 296-301.	2.8	28

#	ARTICLE	IF	CITATIONS
37	Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study. <i>F1000Research</i> , 2017, 6, 2172.	0.8	26
38	Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing—remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004, 224, 23-27.	0.3	24
39	The neurobiological underpinning of the social cognition impairments in patients with spinocerebellar ataxia type 2. <i>Cortex</i> , 2021, 138, 101-112.	1.1	22
40	Brainstem signs with progressing atrophy of medulla oblongata and upper cervical spinal cord. <i>Lancet Neurology</i> , The, 2007, 6, 562-570.	4.9	21
41	Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study. <i>F1000Research</i> , 2017, 6, 2172.	0.8	21
42	Heterozygous <i>KIF1A</i> variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. <i>Journal of Medical Genetics</i> , 2021, 58, 475-483.	1.5	21
43	Machine Learning Use for Prognostic Purposes in Multiple Sclerosis. <i>Life</i> , 2021, 11, 122.	1.1	21
44	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>European Journal of Human Genetics</i> , 2012, 20, 20-26.	1.4	20
45	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLOS Currents</i> , 2011, 3, RRN1247.	1.4	20
46	Impaired vasoreactivity in mildly disabled CADASIL patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 268-274.	0.9	18
47	Functional Changes of Mentalizing Network in SCA2 Patients: Novel Insights into Understanding the Social Cerebellum. <i>Cerebellum</i> , 2020, 19, 235-242.	1.4	17
48	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. <i>Stroke</i> , 2014, 45, 2959-2966.	1.0	16
49	Propriospinal myoclonus with life threatening tonic spasms as paraneoplastic presentation of breast cancer. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 77, 422-424.	0.9	15
50	A Novel Polymorphic AP—1 Binding Element of the <i>GFAP</i> Promoter is Associated with Different Allelic Transcriptional Activities. <i>Annals of Human Genetics</i> , 2010, 74, 506-515.	0.3	14
51	Analyzing the Effects of a G137V Mutation in the <i>FXN</i> Gene. <i>Frontiers in Molecular Neuroscience</i> , 2015, 8, 66.	1.4	14
52	The cerebellar topography of attention sub-components in spinocerebellar ataxia type 2. <i>Cortex</i> , 2018, 108, 35-49.	1.1	14
53	MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. <i>Microorganisms</i> , 2021, 9, 1132.	1.6	14
54	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. <i>Journal of Huntington's Disease</i> , 2018, 7, 209-222.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Multiparametric MR investigation of the motor pyramidal system in patients with "truly benign"™ multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 178-188.	1.4	12
56	A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3696.	1.8	12
57	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross-sectional study. <i>Brain and Behavior</i> , 2021, 11, e02151.	1.0	12
58	Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case report. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	11
59	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2021, 12, 657973.	1.1	11
60	IFN- β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 668-681.	0.5	10
61	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2018, 324, 165-171.	1.1	10
62	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. <i>Clinical Neurology and Neurosurgery</i> , 2018, 168, 60-63.	0.6	9
63	Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4. <i>Neurology: Genetics</i> , 2022, 8, e664.	0.9	9
64	Frataxin deficiency in Friedreich's ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. <i>Human Molecular Genetics</i> , 2020, 29, 471-482.	1.4	8
65	Domestic accidents and multiple sclerosis: an exploratory study of occurrence and possible causes. <i>Disability and Rehabilitation</i> , 2014, 36, 2205-2209.	0.9	7
66	Genome-Wide Multiple Sclerosis Association Data and Coagulation. <i>Frontiers in Neurology</i> , 2019, 10, 95.	1.1	7
67	Disentangling the molecular mechanisms of multiple sclerosis: The contribution of twin studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 111, 194-198.	2.9	7
68	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. <i>Journal of Personalized Medicine</i> , 2022, 12, 36.	1.1	7
69	A shared haplotype for dentatorubropallidoluysian atrophy (DRPLA) in Italian families testifies of the recent introduction of the mutation. <i>Journal of Human Genetics</i> , 2014, 59, 153-157.	1.1	6
70	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	1.8	6
71	Listening to the neurological teams for multiple sclerosis: the SMART project. <i>Neurological Sciences</i> , 2020, 41, 2231-2240.	0.9	6
72	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021, 28, 567-578.	1.7	6

#	ARTICLE	IF	CITATIONS
73	Viruses and neuroinflammation in multiple sclerosis. , 0, , .		6
74	Huntington's disease and suicidal behavior: The importance of lithium treatment. <i>Clinical Neurology and Neurosurgery</i> , 2016, 145, 108-109.	0.6	5
75	Riluzole in patients with hereditary cerebellar ataxia – Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 789.	4.9	5
76	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. <i>Frontiers in Neurology</i> , 2019, 10, 695.	1.1	5
77	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate. <i>Frontiers in Neurology</i> , 2021, 12, 683398.	1.1	5
78	Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. <i>Genes</i> , 2020, 11, 97.	1.0	4
79	Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome. <i>Scientific Reports</i> , 2022, 12, 7536.	1.6	4
80	Multiple sclerosis: pharmacogenomics and personalised drug treatment. <i>Neurological Sciences</i> , 2006, 27, s347-s349.	0.9	2
81	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 83, 380-381.	1.5	2
82	Screening for neurotropic viruses in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. <i>Multiple Sclerosis Journal</i> , 2014, 20, 638-638.	1.4	2
83	Cognitive Dysfunctions in Multiple Sclerosis. , 2013, , 133-153.		1
84	Î2-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 107-124.	0.9	1
85	Effects of the Bacillus Calmette-Guérin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System. , 2014, , 63-80.		1
86	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 83, 293-293.	1.5	1
87	B cell IRF1 pathway is dysregulated in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 1.	1.1	1
88	Upcoming Meetings Related to Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 135-135.	0.9	0
89	160. <i>Cytokine</i> , 2014, 70, 67.	1.4	0
90	Spinocerebellar Ataxia Type 3 in Italy: Time to Change Mind. <i>Neuroepidemiology</i> , 2016, 46, 268-268.	1.1	0

#	ARTICLE	IF	CITATIONS
91	D6â€¦Dna damage in lymphocytes as a predictor of illness evolution in pre-manifest and overt huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.3-A36.	0.9	0
92	Chemical Elements and Oxidative Status in Neuroinflammation. , 2017, , 67-81.		0
93	Bacille Calmette-GuÃ©rin (BCG) Vaccine in Neuroinflammation. , 2018, , 25-38.		0
94	F19â€¦Cognitive reserve: the leisure time concurs to the cognition performance and to the independence of early huntington disease patients. , 2021, , .		0
95	CWAS-associated variants, non-genetic factors, and transient transcriptome in multiple sclerosis etiopathogenesis: A colocalization analysis. Journal of the Neurological Sciences, 2021, 429, 118157.	0.3	0
96	Clinical and genetic features of a large cohort of Italian SPG4 patients from the D.A.I.S.Y. collaborative network. Journal of the Neurological Sciences, 2021, 429, 118251.	0.3	0
97	Aspetti clinici generali. , 2011, , 3-31.		0
98	Clinical Presentation. , 2013, , 11-19.		0
99	Assessment Instruments. , 2013, , 37-41.		0
100	Etiopathogenesis. , 2013, , 21-25.		0
101	DNA Damage Signatures in Peripheral Blood Cells as Biomarkers in Prodromal Huntington's Disease. SSRN Electronic Journal, 0, , .	0.4	0
102	Leptomeningitis in a Person with Radiologically Isolated Syndrome and Latent Tuberculosis: A Case Report with Implications for Clinical Research. Journal of Medical Imaging and Case Reports, 2018, 02, .	0.1	0
103	D12â€¦DNA damage signatures in peripheral lymphocytes as biomarkers in prodromal huntington disease. , 2018, , .		0
104	Title is missing!. , 2020, 15, e0230219.		0
105	Title is missing!. , 2020, 15, e0230219.		0
106	Title is missing!. , 2020, 15, e0230219.		0
107	Title is missing!. , 2020, 15, e0230219.		0